R. Luengo-fernandez, M. Violato, P. Candio, and J. Leal, Economic burden of stroke across Europe: A population-based cost analysis, Eur. Stroke J, vol.87319, p.0, 2019.

G. B. Collaborators, Global, regional, and national burden of stroke, 1990-2016: A systematic analysis for the Global Burden of Disease Study, Lancet Neurol, vol.18, issue.19, pp.30034-30035, 2016.

N. H. Chia, J. M. Leyden, J. Newbury, J. Jannes, and T. J. Kleinig, Determining the number of ischemic strokes potentially eligible for endovascular thrombectomy: A population-based study, Stroke J. Cereb. Circ, vol.47, pp.1377-1380, 2016.

R. Bhatia, Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: Real-world experience and a call for action, Stroke J. Cereb. Circ, vol.41, p.5, 2010.

K. Y. Lee, Early recanalization after intravenous administration of recombinant tissue plasminogen activator as assessed by pre-and post-thrombolytic angiography in acute ischemic stroke patients, Stroke J. Cereb. Circ, vol.38, pp.192-193, 2007.

J. L. Saver, Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke, N. Engl. J. Med, vol.372, pp.2285-2295, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02007226

P. Mcmeekin, Estimating the number of UK stroke patients eligible for endovascular thrombectomy, Eur. Stroke J, vol.2, p.3, 2017.

G. Tsivgoulis, Eligibility for mechanical thrombectomy in acute ischemic stroke: A phase IV multi-center screening log registry, J. Neurol. Sci, vol.371, pp.96-99, 2016.

D. Tanne, Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: The Multicenter rt-PA Stroke Survey, Circulation, vol.105, pp.1679-1685, 2002.

D. Neurological and P. A. Stroke-rt, Tissue plasminogen activator for acute ischemic stroke, N Engl J Med, vol.333, pp.14333-2401, 1995.

V. E. O'collins, 1,026 experimental treatments in acute stroke, Ann. Neurol, vol.59, pp.467-477, 2006.

E. J. Benjamin, Heart disease and stroke statistics-2018 update: A report from the, American Heart Association. Circulation, vol.137, pp.67-492, 2018.

K. A. Hossmann, The two pathophysiologies of focal brain ischemia: Implications for translational stroke research, J. Cereb. Blood Flow Metab, vol.32, p.186, 2012.

E. Kilic, D. M. Hermann, and K. A. Hossmann, A reproducible model of thromboembolic stroke in mice, NeuroReport, vol.9, pp.2967-2970, 1998.

, Scientific RepoRtS |, vol.10, p.12191, 2020.

Z. Zhang, A new rat model of thrombotic focal cerebral ischemia, J. Cereb. Blood Flow Metab, vol.17, pp.123-135, 1997.

R. S. Rasmussen, K. Overgaard, S. Pakola, and G. Boysen, Effects of microplasmin on recovery in a rat embolic stroke model, Neurol. Res, vol.30, pp.75-81, 2008.

C. Orset, B. Haelewyn, K. Vivien, D. Vivien, and A. R. Young, Rodent Models of Stroke, pp.55-70, 2010.

I. M. Macrae, Preclinical stroke research-advantages and disadvantages of the most common rodent models of focal ischaemia, Br. J. Pharmacol, vol.164, pp.1062-1078, 2011.

D. Kaneko, N. Nakamura, and T. Ogawa, Cerebral infarction in rats using homologous blood emboli: Development of a new experimental model, Stroke J. Cereb. Circ, vol.16, pp.76-84, 1985.

M. Kudo, A. Aoyama, S. Ichimori, and N. Fukunaga, An animal model of cerebral infarction. Homologous blood clot emboli in rats, Stroke J. Cereb. Circ, vol.13, pp.505-508, 1982.

C. X. Wang, K. G. Todd, Y. Yang, T. Gordon, and A. Shuaib, Patency of cerebral microvessels after focal embolic stroke in the rat, J. Cereb. Blood Flow Metab, vol.21, pp.413-421, 2001.

C. Orset, Mouse model of in situ thromboembolic stroke and reperfusion, Stroke J. Cereb. Circ, vol.38, p.0, 2007.

C. Orset, Efficacy of alteplase in a mouse model of acute ischemic stroke: A retrospective pooled analysis, Stroke J. Cereb. Circ, vol.47, pp.1312-1318, 2016.

F. Campos, Fingolimod reduces hemorrhagic transformation associated with delayed tissue plasminogen activator treatment in a mouse thromboembolic model, Stroke J. Cereb. Circ, vol.44, p.3, 2013.

I. Garcia-yebenes, A mouse model of hemorrhagic transformation by delayed tissue plasminogen activator administration after in situ thromboembolic stroke, Stroke J. Cereb. Circ, vol.42, pp.196-203, 2011.

F. L. Langhauser, Thromboembolic stroke in C57BL/6 mice monitored by 9.4 T MRI using a 1H cryo probe, Exp. Transl. Stroke Med, vol.4, 2012.

A. Encarnacion, Long-term behavioral assessment of function in an experimental model for ischemic stroke, J. Neurosci. Methods, vol.196, pp.247-257, 2011.

J. Boltze, The stairway: A novel behavioral test detecting sensomotoric stroke deficits in rats, Artif. Organs, vol.30, pp.756-763, 2006.

J. A. Kleim, J. A. Boychuk, and D. L. Adkins, Rat models of upper extremity impairment in stroke, ILAR J, vol.48, pp.374-384, 2007.

G. J. Del-zoppo, Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke, Ann. Neurol, vol.32, pp.78-86, 1992.

E. Di-cera, Q. D. Dang, and Y. Ayala, Molecular mechanisms of thrombin function, Cell Mol. Life Sci, vol.53, pp.701-730, 1997.

M. Saqqur, Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke, Stroke J. Cereb. Circ, vol.38, pp.948-954, 2007.

E. Broussalis, Current therapies in ischemic stroke. Part B. Future candidates in stroke therapy and experimental studies, Drug Discov. Today, vol.17, p.11, 2012.

A. Durukan and T. Tatlisumak, Acute ischemic stroke: Overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia, Pharmacol. Biochem. Behav, vol.87, pp.179-197, 2007.

R. S. Rasmussen, K. Overgaard, E. S. Hildebrandt-eriksen, and G. Boysen, d-Amphetamine improves cognitive deficits and physical therapy promotes fine motor rehabilitation in a rat embolic stroke model, Acta Neurol. Scand, vol.113, pp.189-198, 2006.

K. Overgaard, R. S. Rasmussen, and F. F. Johansen, The site of embolization related to infarct size, oedema and clinical outcome in a rat stroke model-further translational stroke research, Exp. Transl. Stroke Med, vol.2, 2010.

A. Drieu, Immune responses and anti-inflammatory strategies in a clinically relevant model of thromboembolic ischemic stroke with reperfusion, Transl. Stroke Res, 2019.

L. Roberts and C. Counsell, Assessment of clinical outcomes in acute stroke trials, Stroke J. Cereb. Circ, vol.29, pp.986-991, 1998.

M. D. Hill and A. M. Buchan, & Canadian Alteplase for Stroke Effectiveness Study, I. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study, CMAJ, vol.172, pp.1307-1312, 2005.

W. Hacke, Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke, N. Engl. J. Med, vol.359, pp.1317-1329, 2008.

T. H. Cho, Reperfusion within 6 hours outperforms recanalization in predicting penumbra salvage, lesion growth, final infarct, and clinical outcome, Stroke J. Cereb. Circ, vol.46, pp.1582-1589, 2015.

T. Ueno, Association of survival and hyperthermia after rt-PA for ischemic stroke, Acta Neurol. Scand, vol.138, pp.574-578, 2018.

R. Noor, C. X. Wang, and A. Shuaib, Hyperthermia masks the neuroprotective effects of tissue plaminogen activator, Stroke J. Cereb. Circ, vol.36, pp.665-669, 2005.

A. Garcia-culebras, Toll-like receptor 4 mediates hemorrhagic transformation after delayed tissue plasminogen activator administration in in situ thromboembolic stroke, Stroke J. Cereb. Circ, vol.48, p.6, 2017.

R. M. Dijkhuizen, M. Asahi, O. Wu, B. R. Rosen, and E. H. Lo, Delayed rt-PA treatment in a rat embolic stroke model: Diagnosis and prognosis of ischemic injury and hemorrhagic transformation with magnetic resonance imaging, J. Cereb. Blood Flow Metab, vol.21, pp.964-971, 2001.

W. M. Clark, G. W. Albers, K. P. Madden, and S. Hamilton, The rtPA (alteplase) 0-to 6-hour acute stroke trial, part A (A0276g): Results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators, Stroke J. Cereb. Circ, vol.31, pp.811-816, 2000.

R. G. Nogueira, Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct, N. Engl. J. Med, vol.378, pp.11-21, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02387070

C. Korninger and D. Collen, Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro, Thromb. Haemost, vol.46, pp.561-565, 1981.

A. J. Tomkins, R. J. Hood, C. R. Levi, and N. J. Spratt, Tissue Plasminogen Activator for preclinical stroke research: Neither "rat" nor "human" dose mimics clinical recanalization in a carotid occlusion model, Sci. Rep, vol.5, 2015.

B. Haelewyn, J. J. Risso, and J. H. Abraini, Human recombinant tissue-plasminogen activator (alteplase): Why not use the "human" dose for stroke studies in rats, J. Cereb. Blood Flow Metab, vol.30, p.33, 2010.

, Scientific RepoRtS |, vol.10, p.12191, 2020.

, Franke and Margareta Bergqvist Foundation, Knut and Alice Wallenberg Foundation, Olle Engqvist Foundation, Thure Carlsson Foundation, com/scientificreports/ (Experimental Vascular Research) for the use of their facilities. This work was supported by the Swedish Heart-Lung Foundation, pp.2019-0308, 20170883.